MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Short-term investments$267,281K Cash and cashequivalents$45,540K Prepaid expenses andother current assets$20,076K Total current assets$332,897K Other assets$190K Deferred offering costs$69K Right of use assets -operating leases$13K Total assets$333,169K Total liabilities andstockholders' equity$333,169K Total stockholders'equity$307,224K Total liabilities$25,945K Accumulated deficit-$404,641K Additional paid-in capital$711,847K Total currentliabilities$25,945K Accumulated othercomprehensive income (loss)$14K Common stock 0.0001 parvalue, 200,000,000...$4K Accrued expenses$19,997K Accounts payable$5,934K Operating leaseliabilities$14K
Balance Sheet
source: myfinsight.com

ArriVent BioPharma, Inc. (AVBP)

ArriVent BioPharma, Inc. (AVBP)